Tumour-Associated Endothelial Cell Heterogeneity: From Biological Mechanisms to Precision Vascular Targeting
Expert Reviews in Molecular Medicine · 2026 · 28
DOI: 10.1017/erm.2026.10078 ↗Abstract
Abstract Background Tumour-associated endothelial cells (TECs) are heterogeneous and plastic regulators of the tumour microenvironment. Their angiogenic, metabolic, barrier, and immunoregulatory programs influence tumour perfusion, metastatic dissemination, immune-cell access, and therapeutic response. However, the causal roles and clinical utility of many newly identified endothelial states remain uncertain. Methods This review examines the origins and functional heterogeneity of TECs, drawing on findings from single-cell and spatial studies. It discusses the implications of endothelial states for anti-angiogenic therapy, vascular normalization, immune modulation, drug delivery, combination treatment, and therapeutic resistance. Results Current evidence reveals endothelial states with distinct functional and therapeutic properties, although most remain descriptively characterized and lack causal or clinical validation. We propose a translational framework integrating single-cell and spatial profiling with protein-level validation, functional perturbation, vascular imaging, and longitudinal biomarkers to distinguish endothelial states that warrant suppression, normalization, reprogramming, or selective targeting. Conclusions TEC heterogeneity provides a rationale for precision vascular targeting. Establishing the causal functions and therapeutic relevance of endothelial states will be essential to advance vascular therapy beyond empirical angiogenesis inhibition and guide more selective treatment strategies.
EUVIMED